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Abstract 
Purpose: While protocols regarding how to treat status epilepticus (SE) has been universally accepted, 
management of refractory status epilepticus (RSE) is far from being evidence-based. Ketamine (KET), a 
NMDA-antagonist, may have a role in RSE when other conventional anesthetics fail due to its unique 
pharmacodynamic properties and good safety profile. 
Methods: Exhaustive search of available medical literature was performed using MEDLINE-Ovid, 
MEDLINE-PubMed, Psych INFO, Web of Science, and CINAHL for relevant articles from 2012-2017 using 
keywords “ketamine” and “status epilepticus.” Additional criteria for consideration: articles applicable to 
the topic and published in the English language. Exclusion criteria includes all opinion articles, preclinical 
data, protocol articles, and case studies. Studies were then assessed for quality using GRADE criteria. 
Results: The 4 studies reviewed found a good response rate ranging from 64-80% when KET was used as 
the first- or second-line agent in RSE. Furthermore, all studies found a good safety profile of KET at high 
doses and long duration of infusion. Although initial response rate of RSE to early administration of KET is 
high, all 4 studies have severe limitations. 
Conclusion: Currently, RSE algorithms are inadequate and leave providers to choose the best course of 
action. Earlier introduction of KET after failure of first- and second-line agents shows promise to control 
RSE and avoid intubation and ventilation. This area of study needs larger, prospective, and randomized 
trials that clearly designate and follow a protocol to assess adequate efficacy of early administration of 
KET in RSE. 
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Abstract 
Purpose: While protocols regarding how to treat status epilepticus 
(SE) has been universally accepted, management of refractory status 
epilepticus (RSE) is far from being evidence-based. Ketamine (KET), a 
NMDA-antagonist, may have a role in RSE when other conventional 
anesthetics fail due to its unique pharmacodynamic properties and 
good safety profile. 
Methods:  Exhaustive search of available medical literature was 
performed using MEDLINE-Ovid, MEDLINE-PubMed, Psych INFO, Web 
of Science, and CINAHL for relevant articles from 2012-2017 using 
keywords “ketamine” and “status epilepticus.” Additional criteria for 
consideration: articles applicable to the topic and published in the 
English language. Exclusion criteria includes all opinion articles, 
preclinical data, protocol articles, and case studies. Studies were then 
assessed for quality using GRADE criteria. 
Results: The 4 studies reviewed found a good response rate ranging 
from 64-80% when KET was used as the first- or second-line agent in 
RSE. Furthermore, all studies found a good safety profile of KET at 
high doses and long duration of infusion. Although initial response rate 
of RSE to early administration of KET is high, all 4 studies have severe 
limitations. 
Conclusion:  Currently, RSE algorithms are inadequate and leave 
providers to choose the best course of action. Earlier introduction of 
KET after failure of first- and second-line agents shows promise to 
control RSE and avoid intubation and ventilation. This area of study 
needs larger, prospective, and randomized trials that clearly designate 
and follow a protocol to assess adequate efficacy of early 
administration of KET in RSE.  
Keywords: ketamine, status epilepticus, children, adults, refractory 
status epilepticus 
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Early Administration of Ketamine in Refractory 
Status Epilepticus 
 
BACKGROUND 
Status Epilepticus and Refractory Status Epilepticus Defined 
Status epilepticus (SE) is a relatively common life-threatening emergency that can 
be defined as 5 or more minutes of continuous seizure activity or intermittent seizures 
without full recovery between episodes.1 The timing is disputed in older studies2,3 with 
references to SE seizures lasting at least 30 minutes. SE that is resistant to 2 antiepileptic 
drugs (AED) is defined as refractory status epilepticus (RSE), occurring between 30-43% 
of all patients that initially present with a SE episode.4,5 RSE is associated with prolonged 
hospital length of stay,6 increased costs,7 and significant morbidity and mortality.1,6  
 
Current Treatment Protocol 
To provide guidance regarding treatment of SE, the Neurocritical Care Society 
and American Epilepsy Society have developed evidence and consensus-based guidelines 
to assist with therapy. These guidelines focus on the use of AEDs – IV benzodiazepines, 
phenytoin, fosphenytoin, and phenobarbital – at weight-based loading doses (see Figure 1 
and 2). AEDs modify the excitability of the nervous system by inhibiting sodium currents 
or by enhancing GABA (gamma-aminobutyric acid) effects through the GABAA 
receptor.9  
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Once these measures fail to control a seizure, RSE treatment is based on type of 
seizure (convulsive vs. nonconvulsive) and the individual patient’s comorbidities.10 There 
is a consensus that all patients with RSE require respiratory and hemodynamic 
monitoring and support in addition to continuous EEG (cEEG) monitoring,1 but data10,11 
supporting specific therapy is limited and even varies between medical centers based on 
provider preference. UpToDate12 lists the primary drugs for RSE as high-dose midazolam 
(MDZ), propofol (PRO), and barbiturates (eg, pentobarbital, thiopental, or 
phenobarbital). Factors that one must consider when selecting RSE therapy are 
comorbidities of the patient,13,14 type of seizure activity,10 pharmacokinetics of each 
drug,15 and drugs that have already been tried.  
 
Additionally, treatment usually involves a combination of both AEDs and 
intravenous anesthetic drugs (IVAD), which may worsen prognosis due to compounding 
of side effects.15 Continuous intravenous (IV) infusion of conventional anesthetics is 
associated with respiratory depression that requires endotracheal tube intubation and 
cardiac depression causing hypotension and low cardiac output.16 This is based largely on 
the pharmacokinetics of conventional anesthetics, which rely on neuronal inhibition 
mediated largely through the GABAA receptor.  
 
cEEG Monitoring 
As stated above, cEEG monitoring during infusion is imperative to assess efficacy 
and guide titration of the drug, while overall directing the plan of care for the patient.17 
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When asked about titration goals while using continuous infusion of AEDs, 56% of 
neurologists in the United States aim for the burst suppression (BS) pattern on the EEG, 
while 42% look for elimination of seizures without BS pattern.18 This suggests that that 
resolution of SE is not always associated with a BS pattern; in fact, KET may cause its 
own morphological EEG changes19 that may potentially be used as a biomarker for RSE 
response in the future.17 
 
Pathophysiology and Neurobiology of RSE 
Common causes of RSE are different than the former SE. While most SE cases 
are due to low AED levels, cerebrovascular disease, alcohol abuse, and CNS infections,20 
the etiology of RSE is associated with conditions with a poorer prognosis, such as 
metabolic abnormalities, encephalitis, and CNS or systemic infections.21-24 Additionally, 
the pharmacokinetics associated with RSE are slightly different. Therefore, it would be 
appropriate to assume that different treatment would be necessary to manage RSE than 
SE. While most seizures can be terminated in a matter of minutes with inhibition of the 
GABA receptor, prolonged seizures cause inhibitory GABA receptors to internalize, 
while excitatory N-methyl-D-aspartate (NMDA) receptors, a type of glutamate receptor, 
are mobilized to the surface of the cell.3 This exchange in receptor dominance is thought 
to be the reason why conventional AEDs become less active and require higher doses 
over the long term.24 Higher doses of conventional anesthetics enhance adverse events 
such as hypotension, immunosuppression, and reduced gastrointestinal motility that 
require special monitoring, endotracheal intubation (ETT), and careful observation.25 In 
RSE cases treated with PRO, clinicians must monitor closely for signs of propofol 
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infusion syndrome (PRIS) – ie. metabolic acidosis, rhabdomyolysis, hyperlipidemia, or 
fatty liver.26 
 
Pharmacology of Ketamine 
Ketamine (KET) may play a role in RSE due to its pharmacodynamic properties. 
Its action is thought to be mediated through non-competitive blockade of the NMDA-
receptor, but its full mechanism is still not fully understood.27 KET has equal amounts of 
2 enantiomers (S)- and (R)-KET that have different pharmacodynamic properties. For 
example, (S)-KET has faster clearance that results in shorter duration of action and faster 
recovery, but has been shown to be no more effective than racemic KET.28 The racemic 
mixture seems to be more readily used and is available in 3 different concentrations: 10 
mg/ml, 50 mg/ml, and 100 mg/ml and may be administered a variety of different routes.12 
 
While KET has been avoided in certain clinical situations due to its stigma of use 
in veterinary medicine, abuse potential,29 and association with adverse events like 
hallucinations30 and increased intracranial pressure (ICP),31 it is an inexpensive drug32 
that has proven that its unique properties allow it to be useful in a variety of different 
clinical applications.29,33 Furthermore, concern of ketamine use increasing ICP stems 
from limited, small sample sized studies34 that have since been challenged by a variety of 
published studies.35,23 Additionally, hallucinations, which occurs in about 20% of the 
adult population36 and even less frequently in the pediatric population, may be reduced 
with premedication with benzodiazepines or other AEDs.32,37 
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The literature has provided good evidence that KET is both safe and efficacious in 
both adult and pediatric populations. For example, thanks to its sympathomimetic effects, 
KET has less hemodynamic complications,25 is considered neuroprotective in 
concomitant traumatic brain injuries,38 improves cerebral perfusion,39 has minimal effects 
on central respiratory drive and produces airway relaxation,29 has anti-inflammatory 
properties,29 and may avoid the need for ETT.16 Animal models40 have demonstrated later 
efficacy (1 hour) compared to early efficacy (15 min) of ketamine, implying that the 
receptor changes that occur in RSE must occur for KET to be effective.  
 
Rationale for Conducting this Systemic Review 
A variety of studies show that ketamine plays a role in RSE, especially as it is the 
only NMDA antagonist currently used in RSE therapy. An increasing number of 
clinicians are not only advocating ketamine use, but earlier introduction of ketamine in 
RSE therapy.16,24,30,41 As Zeiler (2015)41 states, “one could extrapolate that with the 
reasonable success obtained in the cases summarized […] and with earlier 
implementation of NMDA receptor antagonism, less glutamate mediate[d] excitotoxicity 
would occur, and potentially SE would be less refractory.” Unfortunately, it seems the 
majority of the medical community is still reluctant to even use ketamine in the first 
place,15 regardless of the proven benefits of KET administration over conventional 
anesthetics such as vasopressor sparing anesthetic effects, analgesic effects, and lack of 
significant documented adverse events.41 Based on these thoughts, this systematic review 
looks at articles that focus on early administration of KET during RSE treatment. 
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METHODS 
An exhaustive literature search was performed using MEDLINE-Ovid, 
MEDLINE-PubMed, Psych INFO, Web of Science, and CINAHL for relevant articles 
from 2012-2017. Keywords included: “ketamine” and “status epilepticus.” Additional 
inclusion criteria for consideration: articles applicable to the topic and those published in 
the English language. Exclusion criteria included all opinion articles, preclinical data, 
protocol articles, and case studies. In addition to database searches, references from select 
articles were reviewed for potential relevant sources. The selected articles were assessed 
using GRADE criteria to address quality of evidence.42   
RESULTS 
The database search produced 204 articles. After eliminating all duplicate articles 
among the databases, a total of 4 articles16,22,23,30 were found to be relevant to the clinical 
question and met all eligibility criteria. See Table 1.  
 
Rosati et al (2012) 
This unblinded series30 with no concurrent control group (Class IV Study) looked 
at 9 children (age range: 10 months – 10 years old) with RSE that received IV KET. The 
majority of these children were chronic epilepsy patients. From November 2009 to June 
2011, Rosati et al endorsed a treatment protocol for RSE that included IV KET infusion. 
This protocol was as follows: two IV KET boluses were administered 5 minutes apart 
followed by a continuous infusion. Based on clinical and EEG response, the infusion 
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dose was increased every 10 minutes up until a predetermined maximum dose. 
Midazolam was added on to prevent KET side effects and blood tests were performed 
regularly.30 
 
All cases were pre-treated with at least 1 conventional anesthetic. KET was given 
within a median time of 6 days (range: 5 hours – 26 days) of SE therapy and the median 
duration of KET infusion was 6 days (range: 3-17 days). KET was responsible for 
resolution in 6/9 (67%) children, and none of these 6 responders had a SE relapse. Of 
note, BS pattern was obtained in 5/6 (83%) of KET responders. Additionally, none of the 
9 children treated experienced severe adverse events but a slight increase of saliva 
production occurred in all patients during KET administration.  
 
Synowiec et al (2013) 
This analysis22 was performed retrospectively by reviewing adult patient charts 
that 1) indicated RSE based on billing codes assigned at discharge and 2) were between 
Jan 2003 and December 2011. These charts were further reviewed to indicate which 
patients with RSE were treated with KET. After exclusion of patients with inadequate 
data, total number of patients with outcome data was 11. The majority of these patients 
had chronic epilepsy.22 
 
Prior to use of KET, each patient was being treated with a continuous infusion of 
IVAD and were placed on a cEEG monitor (10/11 patients) or intermittent EEG monitor. 
Most patients were bolused with KET (10/11) prior to initiation of continuous KET 
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infusion. Continuous infusion dosing and maximum dose given varied based upon 
preference on clinician and clinical response.22 
 
KET was the second IVAD used in 8/11 (73%) cases. Attempts were made in all 
cases to wean prior IVAD once KET had been introduced, succeeding in 8/11 (73%) 
cases. Overall, KET was the last AED used prior and caused resolution of RSE in 7/11 
(64%) cases. Additionally, 7/11 cases developed hypotension prior to KET that required 
treatment with vasopressors; once KET was added to RSE therapy, 6/7 (85%) patients 
could be weaned from the pressors.22 
 
Gaspard et al (2013) 
This study23 looked at RSE cases treated with IV KET between 1999 and 2012 in 
a multicenter retrospective review of medical and EEG records. Information was obtained 
from a total of 60 RSE episodes (from 46 adults and 12 children) using a standardized 
datasheet from 10 medical centers in both North America and Europe. This study focuses 
on patients with NORSE (new-onset refractory status epilepticus) and acute brain injury, 
an etiology that carries a worse prognostic outcome than cases occurring in the setting of 
chronic epilepsy.23 
 
This study’s protocol always used KET as a part of a multi-drug regimen, and its 
introduction into RSE therapy usually occurred after a mean of 9 days of SE. There was a 
wide variability of how it was administered (with and without use of loading doses, 
duration of infusion, infusion amount).23 
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KET was likely or possibly responsible for resolution of RSE in 19/60 (32%), 
with 7/60 (12%) cases being likely due to KET. Additionally, resolution rate was higher 
when KET was used as third or fourth-line agent in SE (first or second-line in RSE), and 
was responsible for cessation of RSE in 6/10 (60%) of cases. Overall, Gaspard et al 
noticed that a likely response was not observed when 1) infusion rates of KET were 
lower than 0.9 mg/kg/h, 2) KET was introduced 8+ days after SE onset, or 3) after failure 
of 7+ drugs.23 
 
Of the cohort, 52/60 were treated with vasopressors prior to KET; 6/52 were 
weaned, while 21/52 increased vasopressor dosage after initiation of KET. Younger age 
and response to KET were associated with lower mortality. There was no difference in 
functional outcome in survivors based on if they responded to KET or not; therefore, 
duration and dosage of KET was not related to mortality. KET was discontinued in 4/60 
cases due to suspected treatment-related reactions, such as supraventricular tachycardia, 
atrial fibrillation, and a similar infusion reaction to PRIS, but can be related to concurrent 
use of anesthetics.  
  
Ilvento et al (2015) 
This study16 is an extension of the Rosati et al (2012)30 study. Between November 
2009 and February 2015, they looked at 13 children (age range: 2 months – 11 years old) 
with RSE that were treated with IV KET. Most of these children were chronic epilepsy 
patients. Eight children were treated once, 2 were treated twice, and 3 were treated 3 
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times, for a grand total of 19 different treatments. 10/19 of these treatments were with 
(S)-KET, while the remaining 9/19 were treated with racemic KET.16 
 
The use of KET was associated with RSE suppression in 14/19 (74%) episodes, 
and the EEG BS pattern was seen in 10/19 (53%) episodes. There were 5 children that 
were treated with IV KET prior to all conventional anesthetics to help avoid mechanical 
ventilation. SE control was obtained in 4/5 (80%) of these children, thus eliminating the 
need for intubation.16 
DISCUSSION 
The mortality rate for RSE ranges from 16-39% and etiology of SE is still the 
primary and most important determinant of outcome.6,43,44 Even so, it is not advised to 
stop treatment based on duration of SE, as most patients suffering from RSE for extended 
periods of time may recover with a functional outcome.6 During a 1-year follow-up, 50% 
of RSE treated cases in the ICU returned to baseline, whereas 30% of cases had 
functional defects and 20% died.43 Long-term mechanical ventilation,45,17 older age, no 
prior history of seizures or epilepsy, specific seizure types, and coma-induction predicted 
a worse prognosis,45-47 but was not necessarily predictive of a worse outcome.43  
 
As of now, there is no established protocol for treatment of RSE. Studies43 have 
shown that the longer SE goes untreated, the worse the prognosis. Therefore, rapid initial 
treatment can be correlated to better response to treatment and lower mortality rates 
overall.48 It is imperative that we solidify a recognized RSE protocol, as patients tend to 
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fare worse when a recognized protocol was not followed.43 Unfortunately, there are no 
published randomized trials comparing various treatments, and the optimal treatment of 
RSE is far from being evidence based medicine.  
 
Shelth and Gidal (1998)49 first described successful RSE treatment with IV KET 
in a 13- year-old girl with unknown etiology. Since that time, most studies published 
have been pre-clinical studies, case reports, or small sample studies. The above reviewed 
studies30,22,23,16 focus not only incorporating KET into RSE treatment, but advocating for 
earlier treatment with it. The 4 studies found response rates ranging from 64%-80% when 
KET was used as the first- or second-line medication in RSE. Yet these articles are no 
exception to the previous research limitations, as they themselves are small, non-blinded 
studies with subject heterogeneity. As non-established treatment is usually administered 
when RSE is most severe, clinicians cannot rule out spontaneous improvement of RSE.23 
Additionally, concomitant use of many medications during RSE therapy makes it hard to 
assess efficacy of KET alone, and therefore one cannot rule out a cumulative or delayed 
effect of other drugs given. 
 
Overall, there is a reluctance in the medical community to use KET, either due to 
its reputation of causing adverse effects in certain populations or due to lack of 
familiarity with the drug and its mechanism. In fact, in a recent survey50 of neurologists, 
neurosurgeons, and intensivists across Canada, 76% viewed KET as an experimental 
drug. Yet, in the same survey, 68% stated they would consider using KET (again) for SE, 
with 48% stating that they would even consider using it earlier during treatment. 
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Additionally, countless articles30 have found that KET at high doses and long duration is 
safe for use in both adults and children, even rivaling the potential safety of conventional 
anesthetics. It has proven to be respiratory, cardio-, and neuroprotective. Due to these 
unique capabilities, KET use may avoid the requirement for intubation and/or 
vasopressors, decreasing morbidity and mortality of those treated for RSE. 
 
Although larger, prospective, and randomized trials that clearly designate and 
follow a protocol are needed to help further evidence-based management of RSE, there is 
a lack of randomized control trials that have been published. Rosetti et al (2011)51 
initiated a randomized controlled trial (RCT) investigating the best agents for RSE, but it 
was aborted after 3 years due to funding issues and difficulties enrolling a large enough 
cohort. They realized that they needed participation from a larger number of resources in 
order to increase their enrollment. Therefore, they created a multicenter randomized 
sequential trial, Rosati et al (2016).24 Although it is still in the recruitment stage, this 
study is aimed at assessment of efficacy and safety of KET compared to conventional 
anesthetics (midazolam, propofol, barbiturates) in the treatment of RSE in children. 
Unfortunately, these are not the only RCTs that have struggled to recruit participants,52,53 
as RSE is a rare condition. However, Zeiler and West show that 74% of respondents 
would participate in a prospective study evaluating early KET administration in RSE,50 
showing that there is an excitement regarding the possibilities of KET in the 
advancement of RSE therapy.  
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CONCLUSION 
SE is a neurological emergency that requires immediate treatment as means to 
reduce sequela. Guidance in the treatment of SE is well documented and focuses on the 
use of AEDs. Yet when these epileptic episodes become refractory to treatment with 
conventional anesthetics, providers are left using their best judgement for further 
management based on patient’s comorbidities, seizure type, and response to prior drugs.  
While current guidelines for treatment of RSE are lacking, recent studies are 
allowing us better understanding of how to control RSE. The studies presented during 
this systematic review argue for earlier introduction of KET after failure of first- and 
second-line agents, which shows promise to control RSE and avoid intubation and 
ventilation. Nevertheless, its use needs to be investigated further with a standardized 
treatment algorithm in prospective, randomized control trials.  
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Figure 1. Management of SE and RSE12 
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Figure 2. Dosing of medications used in treatment of SE and RSE12 
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Rosati et al (2013) Case Series Very Seriousa Not Serious Not Serious Very Seriousb Unlikely  Very Low 
Synowiec et al (2013) Case Series  Very Seriousacde Seriousf Not Serious Very Seriousb Unlikely  Very Low 
Gaspard et al (2015) 
 
Case Series Very Seriousade Seriousf Not Serious Very Seriousb Unlikely  Very Low 
Ilvento et al (2015) Case Series  Very Seriousa Not Serious Not Serious Very Seriousb Unlikely  Very Low 
 
a non-blinded, no control group, co-administration of other drugs 
b small sample size 
c inadequate follow up 
d incomplete chart documentation 
e variability in timing and dose  
f differences in population 
 
